Bayer HealthCare Reports Positive
Selected Abstract
Bayer HealthCare Reports Positive Preclinical Study Results on Longer-Acting Recombinant Factor VIII Molecules.
PEGylated Forms of Recombinant Factor VIII Show Extended Time of Activity GENEVA, July 12 /PRNewswire/ -- New preclinical data presented at the 21st Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Geneva, Switzerland, demonstrate that PEGylated forms of recombinant ... July 12, 2007; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Bayer HealthCare Reports Positive Preclinical Study Results on Longer-Acting Recombinant Factor VIII Molecules.
|
